Peritoneal Canceromatosis in Malignant Tumors of Various Localizations. Achievements and Prospects

Peritoneal carcinomatosis is viewed by many experts as a terminal illness with an unfavourable course and prognosis. Existing therapies are controversial and exhibit ambiguous efficacy. We review the current state of the art in therapy for peritoneal metastases of various origin and its historical background. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy compound the treatment of choice as achieving the highest survival rates. Palliative surgery and systemic chemotherapy are an alternative that proved even more aggressive and ineffective in comparative survival evaluations. Manifold studies and expert opinions exist on the efficacy and expedience of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of peritoneal carcinomatosis. Today, however, their routine use in everyday practice is hotly debated. Despite an evident progress in managing peritoneal metastases, a series of questions remain unsolved. Contentious research data, late diagnosis, low treatment efficacy in severe peritoneal dissemination, a limited applicability of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, all highlight the importance of inventing and developing novel methods for early high-accuracy diagnosis and careful selection of the treatment strategy. Fundamental knowledge of malignant metastasis underlies the choice of patient management and the innovative toolkit for prevention and treatment of peritoneal carcinomatosis.

1. Pfannenberg C., Schwenzer N.F., Bruecher B.L. State-of-the-artbildgebung bei peritonealkarzinose. Rofo. 2012;184(3):205–13. DOI: 10.1055/s-0031-1281979

2. McMullen J.R.W., Selleck M., Wall N.R., Senthil M. Peritoneal carcinomatosis: limits of diagnosis and the case for liquid biopsy. Oncotarget. 2017;8(26):43481–90. DOI: 10.18632/oncotarget.16480

3. Klumpp B.D., Schwenzer N., Aschoff P., Miller S., Kramer U., Claussen C.D., et al. Preoperative assessment of peritoneal carcinomatosis: intraindividual comparison of 18F-FDG PET/CT and MRI. Abdom Imaging. 2013;38(1):64–71. DOI: 10.1007/s00261-012-9881-7

4. Dohan A., Hobeika C., Najah H., Pocard M., Rousset P., Eveno C. Preoperative assessment of peritoneal carcinomatosis of colorectal origin. J Visc Surg. 2018;155(4):293–303. DOI: 10.1016/j.jviscsurg.2018.01.002

5. Liberale G., Lecocq C., Garcia C., Muylle K., Covas A., Deleporte A., et al. Accuracy of FDG-PET/CT in colorectal peritoneal carcinomatosis: potential tool for evaluation of chemotherapeutic response. Anticancer Res. 2017;37(2):929–34. DOI: 10.21873/anticanres.11401. PMID: 28179354

6. Pfannenberg C., Königsrainer I., Aschoff P., Oksüz M.O., Zieker D., Beckert S., et al. (18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2009;16(5):1295–303. DOI: 10.1245/s10434-009-0387-7

7. Low R.N., Barone R.M., Lucero J. Comparison of MRI and CT for predicting the Peritoneal Cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2015;22(5):1708–15. DOI: 10.1245/s10434-014-4041-7

8. Liang L., Wang W., Zhou N., Guo J., Lu Y., Xu H., et al. Value of preoperative ultrasound in evaluating the peritoneal cancer index of pseudomyxoma peritonei. World J Surg Oncol. 2019;17(1):192. DOI: 10.1186/s12957-019-1730-5

9. Esquivel J., Chua T.C., Stojadinovic A., Melero J.T., Levine E.A., Gutman M., et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010;102(6):565–70. DOI: 10.1002/jso.21601

10. Dromain C., Leboulleux S., Auperin A., Goere D., Malka D., Lumbroso J., et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging. 2008;33(1):87–93. DOI: 10.1007/s00261-007-9211-7

11. Esquivel J., Chua T.C., Stojadinovic A., Melero J.T., Levine E.A., Gutman M., et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010;102(6):565–70. DOI: 10.1002/jso.21601

12. Patel C.M., Sahdev A., Reznek R.H. CT, MRI and PET imaging in peritoneal malignancy. Cancer Imaging. 2011;11(1):123–39. DOI: 10.1102/1470-7330.2011.0016

13. Kauhanen S.P., Komar G., Seppänen M.P., Dean K.I., Minn H.R., Kajander S.A., et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg. 2009;250(6):957–63. DOI: 10.1097/SLA.0b013e3181b2fafa

14. Schmidt S., Meuli R.A., Achtari C., Prior J.O. Peritoneal carcinomatosis in primary ovarian cancer staging: comparison between MDCT, MRI, and 18F-FDG PET/CT. Clin Nucl Med. 2015;40(5):371–7. DOI: 10.1097/RLU.0000000000000768

15. Jaruvongvanich V., Chesta F., Baruah A., Oberoi M., Adamo D., Singh P.G., et al. Palliative treatment for malignant gastrointestinal obstruction with peritoneal carcinomatosis: enteral stenting versus surgery. Endosc Int Open. 2020;8(10):E1487–94. DOI: 10.1055/a-1237-3956

16. Paul Olson T.J., Pinkerton C., Brasel K.J., Schwarze M.L. Palliative surgery for malignant bowel obstruction from carcinomatosis: a systematic review. JAMA Surg. 2014;149(4):383–92. DOI: 10.1001/jamasurg.2013.4059

17. Stewart C.L., Warner S., Ito K., Raoof M., Wu G.X., Kessler J., et al. Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure? Curr Probl Surg. 2018;55(9):330–79. DOI: 10.1067/j.cpsurg.2018.08.004

18. Tentes A.A., Pallas N., Karamveri C., Kyziridis D., Hristakis C. Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer. J BUON. 2018;23(2):482–7. PMID: 29745096

19. Krouse R.S., Nelson R.A., Farrell B.R., Grube B., Juarez G., Wagman L.D., et al. Surgical palliation at a cancer center: incidence and outcomes. Arch Surg. 2001;136(7):773–8. DOI: 10.1001/archsurg.136.7.773

20. Verwaal V.J., van Ruth S., de Bree E., van Sloothen G.W., van Tinteren H., Boot H., et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43. DOI: 10.1200/JCO.2003.04.187

21. Halkia E., Kopanakis N., Nikolaou G., Spiliotis J. Cytoreductive surgery and HIPEC for peritoneal carcinomatosis. A review on morbidity and mortality. J BUON. 2015;20(Suppl. 1):S80–7. PMID: 26051337

22. Sugarbaker P. The Peritoneal Surface Oncology Group International (PSOGI) In: PSOGI.com. [cited 2021 Apr 1]. Available from: http://www.psogi.com/people/paul-sugarbaker/

23. Lemoine L., Sugarbaker P., Van der Speeten K. Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum. World J Gastroenterol. 2016;22(34):7692–707. DOI: 10.3748/wjg.v22.i34.7692

24. Jayne D. Molecular biology of peritoneal carcinomatosis. Cancer Treat Res. 2007;134:21–33. DOI: 10.1007/978-0-387-48993-3_2

25. Li Y., Zhou Y.F., Liang H., Wang H.Q., Hao J.H., Zhu Z.G., et al. Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies. World J Gastroenterol. 2016;22(30):6906–16. DOI: 10.3748/wjg.v22.i30.6906

26. McMullen J.R.W., Selleck M., Wall N.R., Senthil M. Peritoneal carcinomatosis: limits of diagnosis and the case for liquid biopsy. Oncotarget. 2017;8(26):43481–90. DOI: 10.18632/oncotarget.16480

27. Bushati M., Rovers K.P., Sommariva A., Sugarbaker P.H., Morris D.L., Yonemura Y., et al. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2018;44(12):1942–8. DOI: 10.1016/j.ejso.2018.07.003

28. Yonemura Y. The Peritoneal Surface Oncology Group International (PSOGI). In: PSOGI.com. [cited 2021 Apr 1]. Available from: http://www.psogi.com/people/yutaka-yonemura/

29. Li Y. The Peritoneal Surface Oncology Group International (PSOGI). In: PSOGI.com. [cited 2021 Apr 1]. Available from: http://www.psogi.com/people/yan-li/

30. The Peritoneal Surface Oncology Group International (PSOGI) In: PSOGI.com. [cited 2021 Apr 1]. Available from:http://www.psogi.com/psogi/mission-statement-of-psogi/

31. PSOGI-Life Time Achievement Awards In: PSOGI.com. [cited 2021 Apr 1]. Available from: http://www.psogi.com/people/yan-li/

32. Yan T.D., Cao C.Q., Munkholm-Larsen S. A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J Gastrointest Oncol. 2010;2(2):109–16. DOI: 10.4251/wjgo.v2.i2.109

33. Torres I.J., Litterst C.L., Guarino A.M. Transport of model compounds across the peritoneal membrane in the rat. Pharmacology. 1978;17(6):330–40. DOI: 10.1159/000136874

34. Verwaal V.J., van Ruth S., de Bree E., van Sloothen G.W., van Tinteren H., Boot H., et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43. DOI: 10.1200/JCO.2003.04.187

35. Van der Kaaij R.T., Braam H.J., Boot H., Los M., Cats A., Grootscholten C., et al. Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): rationale and design of the PERISCOPE study. JMIR Res Protoc. 2017;6(7):e136. DOI: 10.2196/resprot.7790

36. Koemans W.J., van der Kaaij R.T., Boot H., Buffart T., Veenhof A.A.F.A., Hartemink K.J., et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II). BMC Cancer. 2019;19(1):420. DOI: 10.1186/s12885-019-5640-2

37. Van der Kaaij R.T., Wassenaar E.C.E., Koemans W.J., Sikorska K., Grootscholten C., Los M., et al. Treatment of PERItoneal disease in Stomach Cancer with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: PERISCOPE I initial results. Br J Surg. 2020;107(11):1520–8. DOI: 10.1002/bjs.11588

38. Desiderio J., Chao J., Melstrom L., Warner S., Tozzi F., Fong Y., et al. The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer. 2017;79:1–14. DOI: 10.1016/j.ejca.2017.03.030

39. Seshadri R.A., Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol. 2016;22(3):1114–30. DOI: 10.3748/wjg.v22.i3.1114

40. Sánchez-Hidalgo J.M., Rodríguez-Ortiz L., Arjona-Sánchez Á., Rufián- Peña S., Casado-Adam Á., Cosano-Álvarez A., et al. Colorectal peritoneal metastases: Optimal management review. World J Gastroenterol. 2019;25(27):3484–502. DOI: 10.3748/wjg.v25.i27.3484

41. Glockzin G., Schlitt H.J., Piso P. Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2009;7:5. DOI: 10.1186/1477-7819-7-5

42. Piso P., Glockzin G., von Breitenbuch P., Sulaiman T., Popp F., Dahlke M., et al. Patient selection for a curative approach to carcinomatosis. Cancer J. 2009;15(3):236–42. DOI: 10.1097/PPO.0b013e3181a58f30

43. Nikeghbalian S., Nikoupour H., Dehghani M., Karami M.Y., Hemati R. Cytoreductive surgery and hyperthermic intraoperative chemotherapy for management of peritoneal carcinomatosis. Arch Iran Med. 2018;21(4):158–63. PMID: 29693406

44. Nesher E., Greenberg R., Avital S., Skornick Y., Schneebaum S. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in peritoneal carcinomatosis. Isr Med Assoc J. 2007;9(11):787–90. PMID: 18085034

45. Spiliotis J.D., Halkia E., Boumis V.A., Vassiliadou D.T., Pagoulatou A., Efstathiou E. Cytoreductive surgery and HIPEC for peritoneal carcinomatosis in the elderly. Int J Surg Oncol. 2014;2014:987475. DOI: 10.1155/2014/987475

46. Baratti D., Kusamura S., Deraco M. The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4–6, 2006): methodology of disease-specific consensus. J Surg Oncol. 2008;98(4):258–62. DOI: 10.1002/jso.21056

47. Mo S., Cai G. Multidisciplinary Treatment for Colorectal Peritoneal Metastases: Review of the Literature. Gastroenterol Res Pract. 2016;2016:1516259. DOI: 10.1155/2016/1516259

48. Montori G., Coccolini F., Ceresoli M., Catena F., Colaianni N., Poletti E., et al. The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art. Int J Surg Oncol. 2014;2014:912418. DOI: 10.1155/2014/912418

49. Yonemura Y., Elnemr A., Endou Y., Hirano M., Mizumoto A., Takao N., et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. 2010;2(2):85–97. DOI: 10.4251/wjgo.v2.i2.85

50. Rovers K.P., Bakkers C., Simkens G.A.A.M., Burger J.W.A., Nienhuijs S.W., et al. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer. 2019;19(1):390. DOI: 10.1186/s12885-019-5545-0

51. Seshadri R.A., Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol. 2016;22(3):1114–30. DOI: 10.3748/wjg.v22.i3.1114